ALLMedicine™ Alopecia Center

May 24th, 2022 - Males with early-onset androgenic alopecia are characterized by elevated androgen levels. The aim of the present study was to investigate whether the presence of this condition modulates the impact of metformin on pituitary hormone production. Thi...

May 22nd, 2022 - Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia.|2022|Sanabria BD,Palmegiani E,Seron AF,Perdomo YC,Miot HA,|

May 20th, 2022 - Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia.|2022|Collins M,Ali S,Wiss IP,Senna MM,|

May 18th, 2022 - In this study, we aimed to explore the expression of the Aicardi-Goutières syndrome (AGS) mutant gene SAMHD1 in paediatric-onset systemic lupus erythematosus (pSLE), its correlations with clinical and laboratory parameters, and the relationship be...

May 18th, 2022 - There may be an association between increased intestinal permeability and the progression of alopecia areata (AA). The present study aimed to investigate the role of intestinal permeability in the etiopathogenesis of AA and its association with th...

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

May 18th, 2022 - To evaluate the safety and tolerability of TDM-105795 administered topically in healthy male subjects with androgenetic alopecia(AGA ). To evaluate the pharmacokinetics (PK)/Pharmacodynamics (PD) of TDM-105795 following administration of a single ...

May 18th, 2022 - This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning ...

May 13th, 2022 - Proposed is an open label trial of tattoo machine microneedling in ten patients with androgenic alopecia. Ten healthy male patients older than 18 years will undergo 6 microneedling sessions. Over the course of six months, subjects will undergo up ...

May 9th, 2022 - Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral fin...

Apr 12th, 2022 - Methods / trial design: Randomised, double-blind, vehicle-controlled multicentre trial in parallel groups. At screening (Visit 0), subjects will discontinue their previous treatment for alopecia areata, if any. Screening period will last up to 28 ...

May 20th, 2022 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata (AA). The development, whi...

May 12th, 2022 - Core Messages Two phase 3 studies, each running for 36 weeks, have proven the efficacy of the Janus kinase inhibitor baricitinib (Olumiant) for patients with alopecia areata. Almost a quarter of participants achieved the therapeutic aim of 80% hai...

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

Apr 28th, 2022 - To the Editor: A 57-year-old man with hypertension, dyslipidemia, and congestive heart failure presented with a disfiguring eruption comprised of asymptomatic papules on the face that appeared 12 months post–heart transplantation. Immunosuppressiv.

Apr 18th, 2022 - Differentiated thyroid cancer (DTC) makes up approximately 95% of all thyroid cancers and is becoming more prevalent worldwide.1 A decade ago, treatment options for DTC were limited but today a plethora of targeted treatments are available. There ...